University of Copenhagen

Statens Serum Institute

Harold Wood Hospital

Michael Christiansen

Ulla M Wewer

Jennie Laigaard

Bent Norgaard-Pedersen

Camilla Frohlich

Bent Nørgaard-Pedersen

Camilla Fröhlich

Kevin Spencer

Camilla Frölich

The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.

ADAM12, a novel marker for abnormal cell function

Growing community of inventors

Holte, Denmark

Michael Christiansen